Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) EBITDA (2016 - 2020)

Historic EBITDA for Larimar Therapeutics (LRMR) over the last 7 years, with Q1 2020 value amounting to -$3.6 million.

  • Larimar Therapeutics' EBITDA rose 7245.76% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 3867.02%. This contributed to the annual value of -$45.3 million for FY2019, which is 2609.1% up from last year.
  • As of Q1 2020, Larimar Therapeutics' EBITDA stood at -$3.6 million, which was up 7245.76% from -$7.3 million recorded in Q4 2019.
  • Larimar Therapeutics' 5-year EBITDA high stood at -$3.6 million for Q1 2020, and its period low was -$17.5 million during Q1 2016.
  • Over the past 5 years, Larimar Therapeutics' median EBITDA value was -$13.1 million (recorded in 2017), while the average stood at -$12.9 million.
  • As far as peak fluctuations go, Larimar Therapeutics' EBITDA tumbled by 3006.83% in 2016, and later skyrocketed by 7245.76% in 2020.
  • Over the past 5 years, Larimar Therapeutics' EBITDA (Quarter) stood at -$10.5 million in 2016, then decreased by 25.47% to -$13.1 million in 2017, then decreased by 11.13% to -$14.6 million in 2018, then surged by 50.21% to -$7.3 million in 2019, then surged by 50.37% to -$3.6 million in 2020.
  • Its EBITDA stands at -$3.6 million for Q1 2020, versus -$7.3 million for Q4 2019 and -$12.9 million for Q3 2019.